Clinical Trials
193
Trial Phases
4 Phases
Drug Approvals
34
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (122 trials with phase data)• Click on a phase to view related trials
News
Johnson & Johnson Seeks European Approval to Expand AKEEGA for Metastatic Prostate Cancer with Genetic Alterations
Janssen-Cilag applied to the European Medicines Agency to expand AKEEGA usage for adults with metastatic hormone-sensitive prostate cancer who have homologous recombination repair gene alterations.
European Commission Approves Darzalex SC with VRd for Newly Diagnosed Multiple Myeloma
The European Commission has approved Darzalex subcutaneous formulation (SC) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplant (ASCT).
European Study Reveals Harmful Impact of Delayed Myasthenia Gravis Diagnosis
A new European study finds patients with myasthenia gravis wait an average of 363 days for accurate diagnosis, with over 27% experiencing delays exceeding one year.
Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) Regimen Shows Significant Benefit in Relapsed/Refractory Multiple Myeloma
The DREAMM-7 study demonstrated that belantamab mafodotin, bortezomib, and dexamethasone (BVd) significantly improved progression-free survival in relapsed/refractory multiple myeloma patients compared to daratumumab, bortezomib, and dexamethasone (DVd).
NICE Declines NHS Coverage of Spravato for Treatment-Resistant Depression Citing Cost and Clinical Concerns
• The UK's healthcare cost-effectiveness agency NICE has rejected Johnson & Johnson's nasal spray antidepressant Spravato for NHS funding, citing concerns over its £10,500 per course price tag and clinical evidence gaps. • NICE highlighted uncertainties about Spravato's long-term efficacy maintenance and lack of comparative data against existing treatments like ECT and psychological therapies for treatment-resistant depression. • Janssen-Cilag, J&J's pharmaceutical unit, criticized the decision, arguing it could deny access to a needed treatment option for patients with treatment-resistant major depressive disorder, affecting up to 30% of depression cases.